A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases
This paper reports the preclinical efficacy of ALD-R491, a vimentin-targeting compound, in treating COVID-19 by reducing viral entry, enhancing pathogen clearance, and suppressing overreactive immune responses.